MMNFQ (MedMen Enterprises) YoY EBITDA Growth: -300.00% (As of Mar. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MedMen Enterprises YoY EBITDA Growth?

MedMen Enterprises MMNFQ -90.00% YoY EBITDA Growth is -300.00% as of Mar. 2023.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. MedMen Enterprises's YoY EBITDA Growth for the quarter that ended in Mar. 2023 was -300.00%.

MedMen Enterprises's EBITDA per Share for the three months ended in Mar. 2023 was $-0.02.

MedMen Enterprises YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for MedMen Enterprises's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedMen Enterprises YoY EBITDA Growth Chart

MedMen Enterprises Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 90.30 5.67 25.10 94.95 -19.23

MedMen Enterprises Quarterly Data
Apr18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 89.47 -368.75 66.67 0.00 -300.00

MedMen Enterprises YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

MedMen Enterprises's YoY EBITDA Growth for the fiscal year that ended in Jun. 2022 is calculated as:

YoY EBITDA Growth (A: Jun. 2022 )
=(EBITDA per Share (A: Jun. 2022 )-EBITDA per Share (A: Jun. 2021 ))/ | EBITDA per Share (A: Jun. 2021 ) |
=(-0.093--0.078)/ | -0.078 |
=-19.23 %

MedMen Enterprises's YoY EBITDA Growth for the quarter that ended in Mar. 2023 is calculated as:

YoY EBITDA Growth (Q: Mar. 2023 )
=(EBITDA per Share (Q: Mar. 2023 )-EBITDA per Share (Q: Mar. 2022 )) / | EBITDA per Share (Q: Mar. 2022 )) |
=(-0.016--0.004)/ | -0.004 |
=-300.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -300.00% mean?
MedMen Enterprises (MMNFQ) has a YoY EBITDA Growth of -300.00% as of Mar. 2023. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for MedMen Enterprises and its competitors.
Is MedMen Enterprises' YoY EBITDA Growth too high?
MedMen Enterprises' current YoY EBITDA Growth is -300.00%.
How does MedMen Enterprises' YoY EBITDA Growth compare to ZTS and VTRS?
MedMen Enterprises' YoY EBITDA Growth of -300.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for MedMen Enterprises and its competitors. MedMen Enterprises's current YoY EBITDA Growth is -300.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedMen Enterprises stock overvalued right now?
MedMen Enterprises (MMNFQ) has a current YoY EBITDA Growth of -300.00%. The current YoY EBITDA Growth is -300.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For MedMen Enterprises (MMNFQ), the current YoY EBITDA Growth is -300.00% as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MedMen Enterprises Business Description

Address 8740 S Sepulveda Boulevard, Suite 105, Los Angeles, CA, USA, 90045
MedMen Enterprises Inc is a American cannabis company dedicated to improving life with Cannabis for All. With operations across the United States in California, Nevada, Illinois, Arizona, Massachusetts, and New York, the company has MedMen and LuxLyte brands offering cannabis in consumer-preferred product forms for medical and recreational use. It produces and curates the consumer product assortment for retail operations in its local communities, and drives consumer loyalty with service and engaging in-store experience, combined with reward, delivery, and e-commerce programs.